Suppr超能文献

基层医疗医生对晚期慢性肾脏病患者2型糖尿病的治疗

Treatment of Type 2 Diabetes Mellitus in Advanced Chronic Kidney Disease for the Primary Care Physician.

作者信息

Mallappallil Mary, Sasidharan Sandeep, Sabu Jacob, John Sabu

机构信息

Internal Medicine and Nephrology, New York City (NYC) Health + Hospitals/Kings County Hospital Center, Brooklyn, USA.

Internal Medicine and Nephrology, State University of New York (SUNY) Downstate University of Health Sciences, Brooklyn, USA.

出版信息

Cureus. 2024 Jul 16;16(7):e64663. doi: 10.7759/cureus.64663. eCollection 2024 Jul.

Abstract

Diabetes mellitus (DM) is a common cause of chronic kidney disease (CKD), leading to the need for renal replacement therapy (RRT). RRT includes hemodialysis (HD), peritoneal dialysis (PD), kidney transplantation (KT), and medical management. As CKD advances, the management of DM may change as medication clearance, effectiveness, and side effects can be altered due to decreasing renal clearance. Medications like metformin that were safe to use early in CKD may build up toxic levels of metabolites in advanced CKD. Other medications, like sodium-glucose co-transporter 2 inhibitors, which work by excreting glucose in the urine, may not be able to work effectively in advanced CKD due to fewer working nephrons. Insulin breakdown may take longer, and both formulation and dosing may need to be changed to avoid hypoglycemia. While DM control contributes to CKD progression, effective DM control continues to be important even after patients have been placed on RRT. Patients on RRT are frequently taken care of by a team of providers, including the primary care physician, both in and outside the hospital. Non-nephrologists who are involved with the care of a patient treated with RRT need to be adept at managing DM in this population. This paper aims to outline the management of type 2 DM in advanced CKD.

摘要

糖尿病(DM)是慢性肾脏病(CKD)的常见病因,会导致需要进行肾脏替代治疗(RRT)。RRT包括血液透析(HD)、腹膜透析(PD)、肾移植(KT)和药物治疗。随着CKD的进展,DM的管理可能会发生变化,因为肾脏清除率降低会改变药物清除率、有效性和副作用。在CKD早期使用安全的药物,如二甲双胍,在晚期CKD中可能会积聚有毒水平的代谢产物。其他药物,如钠-葡萄糖协同转运蛋白2抑制剂,其作用是通过尿液排泄葡萄糖,在晚期CKD中由于有功能的肾单位减少可能无法有效发挥作用。胰岛素分解可能需要更长时间,并且可能需要改变剂型和剂量以避免低血糖。虽然控制DM会促进CKD进展,但即使患者已开始接受RRT,有效控制DM仍然很重要。接受RRT的患者通常由包括初级保健医生在内的一组医疗人员在医院内外进行护理。参与接受RRT治疗患者护理的非肾病科医生需要善于管理该人群的DM。本文旨在概述晚期CKD中2型DM的管理。

相似文献

3
[REIN Report 2011--summary].[2011年肾脏疾病改善全球结果(KDIGO)报告——摘要]
Nephrol Ther. 2013 Sep;9 Suppl 1:S3-6. doi: 10.1016/S1769-7255(13)70036-1.
4
Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022.慢性肾脏病患者的糖尿病管理:2022年核心课程
Am J Kidney Dis. 2022 May;79(5):728-736. doi: 10.1053/j.ajkd.2021.05.023. Epub 2021 Sep 30.
7
Renal replacement therapy in Latin American end-stage renal disease.拉丁美洲终末期肾病的肾脏替代治疗
Clin Kidney J. 2014 Aug;7(4):431-436. doi: 10.1093/ckj/sfu039. Epub 2014 May 23.

本文引用的文献

4
Tirzepatide and prevention of chronic kidney disease.替尔泊肽与慢性肾脏病的预防
Clin Kidney J. 2022 Dec 23;16(5):797-808. doi: 10.1093/ckj/sfac274. eCollection 2023 May.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验